Plasma Protein Therapeutics Assoc

What it reported doing in 2025

As a trusted partner to health systems, ppta drives broad and reliable access to high-quality plasma protein therapies, with a focus on the well- being of patients and plasma donors. The plasma protein therapeutics association (ppta) represents a unique sector of the biologics and biotechnology industry. Ppta represents more than 1,000 human plasma collection centers in north america and europe, as well as the manufacturers of lifesaving plasma protein therapies. Our members produce approximately 80% of the plasma protein therapies in the u.s. And 60% of those manufactured in europe. Ppta works globally to advocate for patient access to plasma-derived medicines, responsibly improve the availability of plasma, and advance the understanding of the plasma ecosystem: -promote clinician authority and patient participation in treatment decisions -pursue reimbursement models recognizing the unique nature of plasma protein therapies -shape decisions of authorities to improve plasma protein therapy availability -forage partnerships that support patient-focused initiatives -advocate for global sufficiency of plasma -pioneer plasma safety and manufacturing quality and support donor well- being -drive progressive policies for plasma collections -encourage plasma donation, globally -generate and promote evidence-based information about plasma -explain the importance, unique nature, and value of plasma protein therapies plasma and plasma collection: plasma is the clear, straw-colored liquid portion of blood that remains after red blood cells, white blood cells, platelets and other cellular components are removed. It is the single largest component of human blood, comprising about 55 percent, and contains water, salts, enzymes, antibodies and other proteins. -composed of 90% water, plasma is a transporting medium for cells and a variety of substances vital to the human body. -plasma carries out a variety of functions in the body, including clotting blood, fighting diseases and other critical functions. -source plasma is plasma that is collected from healthy, voluntary donors through a process called plasmapheresis and is used exclusively for further manufacturing into final therapies (fractionation). Source plasma donors may be compensated for their time and effort. -recovered plasma is collected through whole blood donation in which plasma is separated from its cellular components. Recovered plasma may be used for fractionation. Source plasma is collected through a process called plasmapheresis. In more than 1,000 specialized donation centers located in the u.s. And europe, individuals may donate plasma. Plasmapheresis is a sterile, self-contained, automated process that separates plasma from red blood cells and other cellular components which are then returned to the donor. Source plasma collection in the u.s. Is regulated by the u.s. Food and drug administration (fda) and, in europe, by the european medicines agency (ema) and national regulatory authorities. Plasma manufacturing: source and recovered plasma is the starting material used to manufacture lifesaving therapies. The manufacturing process is known as fractionation. Proteins are separated through this process to create numerous plasma protein therapies. This process is carried out using well-established purification methods such as precipitation, centrifugation, separation, and filtration. Plasma is pooled and processed through a process called "fractionation" that employs time, temperature, ph, and alcohol concentrations to extract specific therapeutic proteins. These are then subjected to various purification methods and viral inactivation and removal processes to further ensure their safety and efficacy. Preparing a therapy often takes from 7-12 months between donation and final product release. This sets the production of plasma protein therapies apart from chemical pharmaceuticals and other biologics whose manufacturing processes are much more condensed and whose direct manu

Financial Efficiency

• Mission deployment rate: 0%; rating input score 0
• Program expense ratio: 0%; rating input score 0
• Fundraising efficiency: Limited

Transparency & Controls

• Consistency checks: 100%; rating input score 100; 64th percentile among comparable filings
• Pay-setting controls: 0 of 6 controls in place; rating input score 0
  • Compensation committee: Missing
  • Independent consultant: Missing
  • Other Form 990s reviewed: Missing
  • Written employment contract: Missing
  • Compensation survey or study: Missing
  • Board or committee approval: Missing
• Foreign activity oversight: Scored; rating input score 0
• Grant itemization coverage: Scored; rating input score 0
• Major donor itemization: Limited
• Related-party transparency: Limited

Accountability

• Independent voting board: 100%; rating input score 100; 64th percentile among comparable filings
• Governance controls: 7 of 9 controls in place; rating input score 78
  • Conflict-of-interest policy: Pass
  • Whistleblower policy: Pass
  • Document-retention policy: Pass
  • CEO compensation review process: Pass
  • Other executive compensation review process: Fail
  • Form 990 shared with the board: Fail
  • Board meeting minutes documented: Pass
  • Audit committee oversight: Pass
  • Independent financial-statement audit: Pass

Sustainability

• Operating margin: -8.9%; rating input score 7; 7th percentile among comparable filings
• Total-asset coverage ratio: 0.73; rating input score 20; 20th percentile among comparable filings
• Liabilities to assets ratio: 0.4; rating input score 32; 32nd percentile among comparable filings
• Officer compensation ratio: 23.2%; rating input score 4; 4th percentile among comparable filings

Growth

• Program expense growth: Limited
• Revenue growth: 3.2% per year; rating input score 100; 24th percentile among comparable filings
• Asset growth: 6.6% per year; rating input score 100; 47th percentile among comparable filings